5.A comparative study between MRI and DSA on diagnosis of spinal dural arteriovenous fistula
Li PAN ; Liangtin MA ; Ze YU
Journal of Interventional Radiology 1994;0(03):-
Objective To evaluate and compare the diagnostic validity of MRI and DSA in patient suspected with spinal dural arteriovenous fistula(SDAVF). Methods A retrospective review on clinical data of 25 cases diagnosed as SDAVF was done to analyze the characteristics of SDAVF on both MRI and DSA. Results The sagittal or cornoral plane of the T 2 -weighted MRI could best show the extraspinal vascular abnormalities and secondary anomalies, while the orifices of the SDAVF, feeding arteries, draining veins could be satisfactorily demonstrated on the DSA. Conclusions The diagnosis of SDAVF can be made in directly on DSA findings, MRI can delineate the extraspinal vascular abnomalities and secondary anomalies but not the whole picture.
6.Surgical treatment of immature teratoma in the anterior skull base with nasal cavity and paranasal sinuses involved via combined approach.
Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2008;43(8):625-626
Adult
;
Craniotomy
;
methods
;
Humans
;
Male
;
Nasal Cavity
;
pathology
;
Paranasal Sinuses
;
pathology
;
Skull Base Neoplasms
;
surgery
;
Teratoma
;
surgery
8.Apoptosis of cervical cancer cell line Hela induced by Livin isoform-specific shRNA
Li-Li YU ; Ze-Hua WANG ;
Chinese Journal of Cancer Biotherapy 1995;0(03):-
Objective: To transfect a recombinant short hairpin RNA(shRNA)expression vector targeting Livin gene isoform(BIRC71,BIRC72)into the cervical cancer cell line(Hela cell),in an attempt to observe RNAi-mediated silen- cing on Livin gene and the induction of Hela apoptosis.Methods: Hela cells were transfected with the recombinant plas- mid pGenesil-1-BIRC71,pGenesil-1-BIRC72 and pGenesil-1-HK via Lipofectamine~(TM)2000.The expression levels of Livin was determined in Hela cells before and after transfection by fluorescence quantitative real-time PCR and Western blotting. The apoptosis rate of cells was determined by FCM 24,48 and 72h after transfection.Results: The transfection efficiency at 48h was higher than those at 24 and 72h.After transfection with pGenesil-1-BIRC71 and pGenesil-1-BIRC72,gene and protein levels of Livin were significantly reduced(P
9.Advances in the Research on the Brucella Intracellular Life
Yu-Fei WANG ; Ze-Liang CHEN ; Liu-Yu HUANG ;
Microbiology 1992;0(06):-
Brucella organisms are facultative intracellular bacteria capable of surviving inside professional and non-professional phagocytes.Upon cell contact the bacteria is internalized via receptor molecules.Once inside cells,Brucella localizes in early phagosomes,where it avoids fusion with late endosomes and lysosomes.Then,the bacterium redirects its trafficking to autophagosomes and finally reaches the endoplasmic reticulum,the replicating niche.Once inside the endoplasmic reticulum,Brucella extensively replicates without restricting basic cellular functions or inducing damage to cells.Invasion,intracellular trafficking and replication of Brucella organisms in professional and non-professional phagocytes and the molecular determinants involving Brucella intracellular life are reviewed in this article.
10.Recent progress in development of antibiotics against Gram-negative bacteria.
Acta Pharmaceutica Sinica 2013;48(7):993-1004
Multidrug-resistant (MDR) bacterial infections, especially those caused by Gram-negative pathogens, have emerged to be one of the world's greatest health threats. However, not only have recent decades shown a steady decline in the number of approved antimicrobial agents but a disappointing discovery also void. The development of novel antibiotics to treat MDR Gram-negative bacteria has been stagnated over the last half century. Though few compounds have shown activities in vitro, in animal models or even in clinical studies, the global antibiotic pipeline is not encouraging. There are a plethora of unexpected challenges that may arise and cannot always be solved to cause promising drugs to fail. This review intends to summarize recent research and development activities to meet the inevitable challenge in restricting the proliferation of MDR Gram-negative bacteria, with focus on compounds that have entered into clinical development stage. In addition to new analogues of existing antibiotic molecules, attention is also directed to alternative strategies to develop antibacterial agents with novel mechanisms of action.
Aminoglycosides
;
pharmacology
;
therapeutic use
;
Animals
;
Anti-Bacterial Agents
;
pharmacology
;
therapeutic use
;
Antibodies, Monoclonal
;
pharmacology
;
therapeutic use
;
Drug Discovery
;
Drug Resistance, Multiple, Bacterial
;
Enzyme Inhibitors
;
pharmacology
;
therapeutic use
;
Ferrous Compounds
;
pharmacology
;
therapeutic use
;
Gram-Negative Bacteria
;
drug effects
;
Gram-Negative Bacterial Infections
;
drug therapy
;
Humans
;
Peptides
;
pharmacology
;
therapeutic use
;
Peptidomimetics
;
pharmacology
;
therapeutic use
;
Tetracyclines
;
pharmacology
;
therapeutic use
;
beta-Lactamase Inhibitors
;
beta-Lactams
;
pharmacology
;
therapeutic use